

Immediate Release

30 November 2007

**ReGen Therapeutics Plc
(‘ReGen’ or the Company’)
Total Voting Rights**

For the purposes of the Disclosure and Transparency Rules of the Financial Services Authority, the Board of ReGen is required to notify the market of the following:

As at the date of this announcement, the Company's issued share capital consists of 10,258,878 ordinary shares with a nominal value of 10 p each, with voting rights (“Ordinary Shares”). The Company does not hold any Ordinary Shares in Treasury.

Therefore the total number of Ordinary Shares in the Company with voting rights is 10,258,878.

The above figure of 10,258,878 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Service Authority’s Disclosure and Transparency Rules.

ENDS

For further information, please contact:

Andrew Marshall
Greycoat Communications
Tel No 020 7960 6007

Percy Lomax – Executive Chairman
ReGen Therapeutics Plc
Tel No 020 7153 4920
Direct No 020 8504 2156

Roland Cornish
Beaumont Cornish Limited
Tel No 020 7628 3396

Nick Bealer
King & Shaxson Capital Limited
Tel No 020 7426 5986